Camber Pharmaceuticals has voluntarily recalled a pneumonia drug due to potential contamination in the product, according to the Food and Drug Administration.
Atovaquone Oral Suspension is being recalled due to a potential Bacillus cereus contamination. The FDA warns that those who are immunocompromised are at the greatest risk from the medication if it is contaminated.
To date, Camber has not received any reports of adverse events related to this recall.
Atovaquone Oral Suspension, USP is indicated for the prevention and treatment of Pneumocystis jiroveci pneumonia (PCP) in adults and children 13 years of age and older who cannot tolerate other medicines, the release said.
Atovaquone Oral Suspension, USP is distributed nationally, and Camber is notifying all of the distributors about the recall.
The product is packaged in a 210 mL HDPE bottle in a mono carton. The identified NDC No. associated with the product is 31722-629-21, UPC No. 331722629218, and the affected lot No. is E220182 with an expiration date of 12/2023.
Those using the medication should stop using it and either return it to the place of purchase or discard it.
Consumers with questions regarding this recall can call 1-877-597-0878 or email rxrecalls@inmar.com, Monday – Friday, 9 a.m. – 5 p.m. EDT. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
©2023 Cox Media Group
